Crossmark

No Increased Risks Associated with Propranolol Treatment for Infantile Hemangioma in Preterm Infants were Identified at 3 Years of Age

Crossref DOI link: https://doi.org/10.1007/s40257-018-00419-1

Published Online: 2019-01-07

Published Print: 2019-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Li, Li

Wei, Li

Xu, Zi-Gang

Ma, Lin
Funding

Funding for this research was provided by:

Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (ZYLX201601)

The Capital Health Research and Development of Special (2016-2-2093)

Beijing Municipal Administration of Hospitals Incubating Program (PX2016014)

Beijing Children?s Hospital Clinic-Scientific Young Investigator Program (BCHYIPB-2016-02)
License Information

Text and Data Mining valid from 2019-01-07
More Information

Article History

First Online: 7 January 2019

Compliance with Ethical Standards

:

: This study was supported by the Capital Health Research and Development of Special (2016-2-2093); Beijing Municipal Administration of Hospitals Incubating Program (PX2016014); Beijing Children’s Hospital Clinic-Scientific Young Investigator Program (BCHYIPB-2016-02); and Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (NO ZYLX201601).

: Li Li, Li Wei, Zi-Gang Xu, and Lin Ma have no conflicts of interest to declare.

: This study was approved by the Ethics Committee of Beijing Children’s Hospital, Capital Medical University (No. [2015]-Y-021-D). The need for informed consent for this retrospective study was waived by the Ethics Committee of Beijing Children’s Hospital, Capital Medical University.